Lilly calls early Foundayo launch encouraging as oral GLP-1 trails Novo
The company's orforglipron pill for obesity is being compared with Novo Nordisk's oral entrant in its first weeks on pharmacy shelves.
MH
By Maren Holt · Senior Reporter, GLP-1
Apr 30 03:00 ETSource: Fierce Pharma
The wire
- 01Lilly executives described early uptake of Foundayo, its oral GLP-1 orforglipron for obesity, as encouraging while acknowledging the pill appears to lag Novo Nordisk's oral rival.
- 02Pharmacists and telehealth operators tracking oral incretin supply and coverage will want to watch whether pill volumes shift demand away from injectable tirzepatide.
- 03Launch-quarter script comparisons are early and reflect company commentary rather than independent data; relative share will not be clear for several quarters.
From the source
Read at fiercepharma.comLilly touts 'encouraging' early days for Foundayo obesity launch, even as GLP-1 pill appears to lag Novo's